CCL18 has been shown to promote immunosuppressive states and progression in esophageal squamous cell carcinoma (23), multiple myeloma (24), osteosarcoma (25), ovarian cancer (26), and renal cell carcinoma (27). This evidence concerns the gene CCL18 and hereditary clear cell renal cell carcinoma.